Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg
NCT03537768 · Kimberly Myer · PHASE4 · terminated · last registry update 2025-11-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “We weren't seeing as many pregnancies we initially thought.” | – | Registry record, Kimberly Myer |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PGR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-27Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Danazol (NCT03312400)
- 2026-10-27Also stopped (terminated): National Heart, Lung, and Blood Institute (NHLBI), Danazol (NCT03312400)
- 2026-10-21Phase 3 first posted: Khyber Medical University Peshawar, Thalidomide + Danazol (NCT07884773)
- 2026-09-16Also stopped (withdrawn): University Hospital, Basel, Switzerland, a drug against PGR (NCT07581600)
- 2026-09-14Results posted on the registry: Mylan Technologies Inc., MR-100A-01 (NCT05139121)
- 2026-08-27Results posted on the registry: Insud Pharma, Twirla® (Levonorgestrel/Ethinyl Estradiol) Transdermal System (NCT07739589)
- 2026-07-30Also stopped (withdrawn): Bayer, BAY865028 + Medroxyprogesterone acetate (NCT06904274)
- 2026-07-29Phase 3 first posted: Chemo Research, Levonorgestrel (NCT07734155)
- 2026-06-30Results posted on the registry: InnovaGyn, Inc., Levonorgestrel 1.5 milligram + Meloxicam 15 milligram (NCT06306131)
- 2026-06-17Results posted on the registry: InnovaGyn, Inc., Levonorgestrel 1.5mg + Meloxicam 15 mg (NCT05695352)
- 2026-06-05Also stopped (withdrawn): University of Chicago, Myfembree Oral Product (NCT05538689)
- 2026-05-13Results posted on the registry: Sumitomo Pharma Switzerland GmbH, Relugolix Combination Therapy (NCT04756037)
- 2026-05-06Results posted on the registry: Boehringer Ingelheim, Microgynon® + Iclepertin (NCT05613777)
- 2026-04-23Results posted on the registry: Sebela Women's Health Inc., LevoCept (NCT02882191)
- 2026-04-23Results posted on the registry: University of Colorado, Denver, Ethinyl Estradiol / Norgestimate Oral Tablet (NCT04828824)
- 2026-04-17Phase 3 first posted: Dr. Hang Wun Raymond Li, Estetrol-drospirenone + Ethinylestradiol-levonorgestrel (NCT07536763)
- 2026-04-01Phase 3 first posted: University of Pennsylvania, 200mg mifepristone and 800mg misoprostol (NCT07506512)
- 2026-03-18Results posted on the registry: Washington University School of Medicine, Mifepristone + Misoprostol (NCT05322252)
- 2026-03-04Phase 3 first posted: University of Utah, Levonorgestrel 1.5 mg and Piroxicam 40 mg + Oral LNG + Placebo (NCT07449299)
- 2026-02-23Also stopped (withdrawn): University of Virginia, Metformin + Oral combined hormonal contraceptives (NCT03905941)
- 2026-02-09Results posted on the registry: Kimberly Myer, Nestorone + Testosterone Combination Gel (NCT02994602)
- 2026-01-23Results posted on the registry: Premier Research, 150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR) (NCT00455156)
- 2026-01-12Also stopped (withdrawn): Washington University School of Medicine, Semaglutide + Placebo (NCT05829460)
- 2026-01-07Results posted on the registry: Premier Research, levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2 + levonorgestrel patch with BMI <32 kg/m2 (NCT01166412)
- 2025-12-23Also stopped (terminated): University of Chicago, Pembrolizumab + Mifepristone (NCT03225547)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision